Comparative Pharmacology
Head-to-head clinical analysis: BROMSITE versus OMIDRIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMSITE versus OMIDRIA.
BROMSITE vs OMIDRIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bromsite (bromfenac ophthalmic solution) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) 1 and 2, thereby reducing prostaglandin synthesis in ocular tissues.
OMIDRIA is a fixed-dose combination of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis, and phenylephrine hydrochloride, an alpha-1 adrenergic receptor agonist that causes vasoconstriction.
1-2 tablets (200-400 mg) orally 3-4 times daily as needed.
1 mL of the fixed-dose combination (ketorolac 0.45% / phenylephrine 1%) administered intracamerally as a single dose at the time of cataract surgery.
None Documented
None Documented
Terminal elimination half-life 12–15 hours; prolonged in renal impairment (up to 30 hours).
Ketorolac: terminal half-life of 5.3 hours (range 3.8-8.2 hours) in adults; phenylephrine: terminal half-life of 2-3 hours. Clinically, ketorolac's half-life supports twice-daily dosing.
Primarily renal excretion of unchanged drug (~70%) and glucuronide conjugate (~20%); minor biliary/fecal elimination (~10%).
Renal elimination of ketorolac accounts for approximately 91% of the dose, with approximately 60% as unchanged drug and the remainder as metabolites; phenylephrine is primarily metabolized and excreted in urine as sulfate conjugates, with <20% excreted unchanged.
Category C
Category C
Ophthalmic NSAID
Ophthalmic NSAID and Mydriatic Combination